<HTML lang="en" dir="ltr" class="client-nojs">
<style type="text/css">
A:before { content:' '; } 
A:after { content:' '; } 
SPAN:before { content:' '; } 
SPAN:after { content:' '; } 
</style>
<BODY class="mediawiki ltr sitedir-ltr ns-0 ns-subject page-Team_Leiden_secret skin-igem action-view"><DIV id="globalWrapper"><DIV id="content" class="mw-body" role="main"><DIV id="top_title"><H1 id="firstHeading" class="firstHeading"><SPAN dir="auto">Team:Leiden/secret</SPAN></H1></DIV><DIV id="HQ_page"><DIV id="bodyContent"><DIV id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><PRE>&lt;nav id=&quot;header_html&quot; data-source=&quot;navbar.html&quot;&gt;&lt;/nav&gt;</PRE><DIV class="container-text"><H1 class="uppercase"><SPAN class="mw-headline" id="Abstract">Abstract</SPAN></H1><P style="font-size:20px;">Antimicrobial resistance poses a serious threat to global public health. The number of drug-resistant pathogenic bacteria is rapidly rising, while only a handful of new marketable antibiotics have been introduced in the past three decades. Most antibiotics
      that are currently in use target an essential cellular process, thereby killing the pathogen. iGEM Leiden aims to establish an innovative screening system that enables us to rapidly discover compounds that stress bacterial cells. We will therefore
      create a library of reporters that respond to stresses in different cellular pathways, by fusing stress-induced promotors to pigmented chromoproteins in <SPAN class="italic">E. coli</SPAN>. In this manner, stress-inducing compounds can be rapidly
      discovered and developed for application in combination therapy, aimed at inducing synthetic lethality.</P></DIV></DIV></DIV></DIV></DIV></DIV></BODY></HTML>